The sustained efficacy and safety data through one year de-risk canvuparatide's Phase 3 program and support a best-in-class profile as a once-weekly PTH replacement therapy. Monitor for Phase 3 initiation in Q3 2026 and potential partnership interest given the large addressable market (>250K patients in US/EU).
Price Chart
Executive Summary
MBX Biosciences announced positive one-year data from the Phase 2 Avail and open-label extension trials of canvuparatide in chronic hypoparathyroidism, showing a 57% responder rate at one year (comparable to 63% at 12 weeks), sustained normalization of serum calcium, reduced urine calcium, improved eGFR, and restored bone metabolism with no new safety signals. The Phase 3 pivotal trial remains on track to initiate in Q3 2026, and the company has $440 million in cash expected to provide runway into 2029.
Key Facts
- 57% responder rate at one year (31/54 evaluable patients) vs 63% at 12 weeks in Phase 2 Avail trial
- 90% retention rate at one year in the open-label extension study
- Mean eGFR increased by 5.3 mL/min/1.73m2 from baseline at one year
- No treatment-related serious adverse events reported; injection site reactions in 10% of patients
- Phase 3 pivotal trial on track to initiate in Q3 2026
- $440 million in cash expected to provide runway into 2029
Financial Impact
No revenue or earnings reported; clinical-stage biotech with $440M cash runway into 2029
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results
- Competition from existing daily PTH therapies (Yorvipath) and other pipeline candidates
- Regulatory approval and commercial launch are years away; company remains pre-revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-268477 |
| Document: mbx-ex99_1.htm | 0001193125-26-268477 |
| Document: mbx-ex99_2.htm | 0001193125-26-268477 |
| Document: 0001193125-26-268477-index-headers.html | 0001193125-26-268477 |
| Document: 0001193125-26-268477-index.html | 0001193125-26-268477 |
| Document: 0001193125-26-268477.txt | 0001193125-26-268477 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $52.74 (+4.52%) |
Oct 22, 2026 5d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $52.74 (+4.52%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $52.74 (−20.56%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $52.74 (−22.73%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $52.74 (−21.41%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $52.74 (+48.52%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $52.74 (+48.52%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $52.74 (+41.58%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $52.74 (+41.58%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $52.74 (+70.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers